Bioniche presents more data on anticancer activity of mycobacterial cell wall-DNA complex

By Elaine Rigoli

Tampa, Fla., June 29 - Bioniche Life Sciences, Inc. made three presentations on the anticancer activity of Mycobacterial Cell-Wall DNA Complex (MCC) against human bladder cancer cells during the 61st annual meeting of the Canadian Urological Association this week in Halifax, Nova Scotia.

The presentations included:

• Effect of Formulation on the Direct Anticancer Activity of MCC Against Human Bladder Cancer Cell Lines;

• MCC Induces Apoptosis Markers and a Cytokine Profile Distinct from BCG Following Repeated Intravesical Administration;

• MCC Has a Direct Anticancer Activity Against Primary Human Bladder Cancer Cell Cultures.

"Anticancer agents for urinary bladder cancer therapy are designed to kill cancer cells directly (chemotherapy effect) or to stimulate the immune response of cancer patients (immunotherapy effect)," said Mario C. Filion, Bioniche's head of biomedical research, in a news release.

"The new and updated data presented this week confirm that MCC is a unique anticancer agent possessing both chemotherapeutic and immunotherapeutic activities following intravesical administration to patients with urinary bladder cancer."

Bioniche is a research-based biopharmaceutical company based in Belleville, Ont.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.